VX-017 blood-type-independent stem-cell islets
Vertex Pharmaceuticals
Phase 1/2 registered; no human outcomes yet.
What it is
Vertex's newly named stem-cell-derived, fully differentiated islet-cell therapy, designed for eligible people with type 1 diabetes regardless of blood type. The FDA has cleared its IND. The 1 September 2026 update to NCT04786262 adds a Phase 1/2 VX-017 arm to the recruiting islet-cell master protocol, with hepatic portal-vein infusion. No VX-017 human outcomes have been reported.
Editorial review: .
Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Preclinical evidence. Benefit in people has not been established.See the linked studies and their populations →
- Benefit or performance
- Insulin independence: VX-017 is intended to replace islet function, but Vertex has disclosed no human efficacy data and has not said that recipients became insulin-free.[1]
- Important harms and treatment burden
- Immunosuppression-free: Vertex has not publicly stated whether VX-017 requires systemic immunosuppression; blood-type independence must not be read as immune evasion or immunosuppression independence.[1]
- Approval and country access
- Trial-only programme. Registry added VX-017 on 1 September 2026; no human outcome or approval timeline is available.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: No participant outcomes have been reported; graft survival and durable glucose control remain unknown.[1]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. This speculative assessment includes intended performance or preclinical findings; it does not establish benefit in people.
Default calculation: 5 × 30 + 5 × 20 + 5 × 20 + 15 × 10 + 20 × 10 = 700; divide by total weight 90. Unrounded weighted result: 7.777777777777778.
VX-017 is intended to replace islet function, but Vertex has disclosed no human efficacy data and has not said that recipients became insulin-free.[1]
No participant outcomes have been reported; graft survival and durable glucose control remain unknown.[1]
Vertex has not publicly stated whether VX-017 requires systemic immunosuppression; blood-type independence must not be read as immune evasion or immunosuppression independence.[1]
Vertex says the product is designed for eligible people with T1D regardless of blood type, but the registered study still restricts enrollment to adults aged 18-65 with at least five years of insulin dependence, recurrent severe hypoglycemia and established CGM use.[2]
Phase 1/2 is now registered as Part D of recruiting master protocol NCT04786262. Registration does not establish VX-017 dosing or efficacy.[2]
The full picture
Vertex disclosed VX-017 on 3 August 2026 as a stem-cell-derived, fully differentiated islet-cell therapy whose FDA investigational new drug application had been cleared.1 The company says it is designed to treat eligible people with type 1 diabetes regardless of blood type and that a Phase 1/2 study will begin in the near term.1
The 1 September 2026 registry update adds VX-017 as Part D of the recruiting master protocol NCT04786262, alongside zimislecel (VX-880). VX-017 is a Phase 1/2 arm despite the master record’s overall Phase 3 label. Both products are infused into the hepatic portal vein. The 57-person enrollment estimate belongs to the whole protocol. Eligibility includes ages 18-65, at least five years of insulin dependence, at least two severe hypoglycemic episodes in the previous year, and established CGM use.2
The public registry does not establish an immune-evasion design or detail the VX-017 immunosuppression regimen. “Regardless of blood type” does not mean “immunosuppression-free.” Registration is also not evidence that VX-017 has been dosed or works: no participant outcomes are reported.2
The next useful evidence is therefore not an approval forecast. It is confirmation of dosing, the immune-management regimen, and whether recipients show safe engraftment and glucose-responsive C-peptide. Vertex expects to provide updated timelines for both VX-017 and zimislecel later in 2026.1
Coming soon
ETA · Phase 1/2 registered within recruiting master protocol NCT04786262. Master-protocol primary completion is estimated for 31 December 2027, with follow-up through 2031; these are not a VX-017 efficacy or approval forecast.
- →First VX-017 dosing confirmation and participant safety/C-peptide results · No outcome date announced
- →Vertex update on the VX-017 development timeline · Expected later in 2026
Sources
- [1]Vertex reports second-quarter 2026 financial results · Manufacturer · 2026-08-03 — Primary company release filed with the SEC. It says the FDA cleared the IND and a Phase 1/2 study is planned in the near term, but gives no route, immune-engineering description, immunosuppression regimen, or human data.
Vertex Pharmaceuticals. Vertex Reports Second Quarter 2026 Financial Results. 3 August 2026.
- [2]Islet-cell master protocol for VX-880 and VX-017 (NCT04786262) · Trial registry · 2026-09-01 — Recruiting master protocol with Phase 1/2/3 VX-880 and Phase 1/2 VX-017. Estimated enrollment 57 is across the protocol, not 57 VX-017 recipients. VX-017 is infused into the hepatic portal vein; Part D prioritizes safety and Day-90 peak C-peptide. No registry results posted.
ClinicalTrials.gov. Islet-cell master protocol for VX-880 and VX-017, NCT04786262; last update posted 1 September 2026, reviewed 16 September 2026.